FDA_TrackerJim said:The pharmacokinetics explain nearly every practical question asked here.
Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.
The figures, for anyone assembling their own picture. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.
Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
Dr.GutHealth said:Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody…
Coming at Dr.GutHealth’s question from a different direction. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsA narrower follow-up, since the general answer is now clear:
Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?
OP back with an update, since a thread like this is useless without one.
Update — tachyphylaxis to the gastric effect, persistence of the appetite effect. Two curves, and I had been watching the wrong one.